Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArdelyxARDX -1.79%68 3-1 Month Momentum % is -19.43% as of Aug. 03, 2026. GuruFocus rates ARDX with a GF Score™ of 68/100 and a GF Value™ of $10.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,389 Biotechnology companies, Ardelyx ranks worse than 68.18% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-03), Ardelyx's 3-1 Month Momentum % is -19.43%.
The industry rank for Ardelyx's 3-1 Month Momentum % or its related term are showing as below:
ARDX's 3-1 Month Momentum % is ranked worse than 68.18% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs ARDX: -19.43
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Ardelyx 3-1 Month Momentum % Related Terms
ARDX vs IMTX, TRAX, AVLN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Ardelyx's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Ardelyx's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (ARDX) has a 3-1 Month Momentum % of -19.43% as of Aug. 03, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #947 out of 1389 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Ardelyx's 3-1 Month Momentum % too high?
Ardelyx's current 3-1 Month Momentum % is -19.43%. Based on the distribution chart, Ardelyx ranks #947 out of 1389 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ardelyx has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's 3-1 Month Momentum % compare to IMTX and TRAX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #947 out of 1389 companies for 3-1 Month Momentum %. This places Ardelyx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ardelyx and its competitors. Ardelyx's current 3-1 Month Momentum % is -19.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is $10.46, compared to a current price of $4.96 — trading 52.6% below its estimated fair value. The current 3-1 Month Momentum % is -19.43%. Ardelyx's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Ardelyx (ARDX), the current 3-1 Month Momentum % is -19.43% as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of $4.96 is trading 52.6% below its estimated GF Value™ of $10.46.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for ARDX:
3-1 Month Momentum %: -19.43%
GF Value™: $10.46 vs. price of $4.96 (52.6% below fair value)
No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
68GF Score
Get the complete analysis for ARDX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARDX has been successfully added to your 
